Filing of eight patent applications

RNS Number : 3245U

e-Therapeutics plc

01 August 2022

 

e-therapeutics plc

("e-therapeutics" or the "Company")

Filing of eight patent applications on

proprietary GalNAc-siRNA technology and target related innovation

London, UK, 1 August 2022 - e-therapeutics plc (AIM: ETX; OTCQX; ETXPF), a specialist in computational drug discovery with a focus on developing RNA interference ("RNAi") therapeutics, today announced the filing of eight further patent applications in the United States ("US") to protect innovation arising from e-therapeutics' proprietary GalNAc-siRNA technology.

The Company uses its proprietary GalNAc-siRNA technology to silence any gene in liver hepatocytes.  As announced on 26 October 2021, e-therapeutics' GalNAc-siRNA constructs have demonstrated compelling in vivo performance in terms of depth of gene silencing and duration of action. 

The eight patent applications relate to innovation arising from the Company's work on its pipeline of pre-clinical siRNA candidates in several therapeutic areas and include innovation around novel target ideas and associated disease-relevant biology identified using the Company's computational platform, novel siRNA therapeutics and novel siRNA chemistries associated with such siRNA therapeutics. 

This news follows e-therapeutics' announcement on 4 May 2022, as part of its year-end results statement, that eleven patent applications had been filed to protect proprietary and novel GalNAc-siRNA silencing construct designs.

Ali Mortazavi, Chief Executive Officer of e-therapeutics, commented:

"This second announcement of significant patent filings within three months demonstrates fast and meaningful scientific and technological progress. It also reflects our commitment to protecting the Company's proprietary innovation, which forms a critical part of our strategy as we continue to make material steps in developing a computationally driven in-house pipeline of highly differentiated RNAi medicines at speed. Our computational platform not only affords us an important advantage in drug discovery, but also in IP strategy, and we are leveraging this position in our patent applications." 

Enquiries:

e-therapeutics plc
Ali Mortazavi, CEO  James Chandler, VP IR & Communications	Tel: [phone] www.etherapeutics.co.uk
SP Angel Corporate Finance LLP	Tel: [phone]
Nominated Adviser and Broker
Matthew Johnson/Caroline Rowe (Corporate Finance)
Vadim Alexandre/Rob Rees (Corporate Broking)

 

About e-therapeutics plc

e-therapeutics plc is a UK-based company integrating computational power and biological insight to accelerate the discovery of life-transforming medicines. The Company has developed and validated a powerful, disease- and modality-agnostic computational approach to drug discovery, leveraging its industry-leading expertise in network biology to capture and interrogate human disease complexity more fully.

The Company's multi-disciplinary team builds computational models of biological functions to transform the search for new medicines, interventions, mechanisms and genetic support. Its biology-led in silico laboratory enables rapid hypothesis generation and screening. Novel targets can also be identified, prioritised and assessed. Harnessing internal target gene discoveries, e- therapeutics is currently building an in-house pipeline of RNAi based medicines, using its proprietary GalNAc-siRNA technology.

e-therapeutics has deployed and validated its computational drug discovery platform both in house and with partners, including Novo Nordisk, Galapagos NV, iTeos and a US-based, top 5 pharmaceutical company.

 

END

 

 

MSCFLFVEDIIAFIF